DAVYDOVA, Y.,
KAZANTSEVA, A.,
ENIKEEVA, R.,
MUSTAFIN, R.,
MALYKH, S.,
LOBASKOVA, M.,
VALINUROV, R.,
AKHMEROVA, I.,
KHUSNUTDINOVA, E. (2020) The involvement of hypothalamic-pituitary-adrenal and monoaminergic
systems genes in developing
WANG, K.,
LIU, H.,
LIU, J.,
WANG, X.,
TENG, L.,
ZHANG, J.,
CHEN, X.,
WANG, N.,
ZHONG, Y.,
HOU, X.,
JIANG, H.,
ZHANG, X.,
ZHAO, S.,
LIU, Y.,
YAO, Y.,
WANG, J.,
QU, Y.,
PENG, F.,
BEYLERLI, O.,
LIAO, X. (2019) that targeting amino acid metabolism such as methionine deprivation/IL1RN related gene
therapy may offer novel
GAREEV, I.F.,
BEILERLI, O.A.,
ALIEV, G.M.,
PAVLOV, VALENTIN,
IZMAILOV, ADEL,
ZHANG, YIWEI,
LIANG, YANCHAO,
YANG, GUANG (2020) aneurysms will have the potential to use lncRNAs in
therapy, as well as in the diagnosis and prediction
BEYLERLI, OZAL,
BEERAKA, NARASIMHA M.,
GAREEV, ILGIZ,
PAVLOV, VALENTIN,
YANG, GUANG,
LIANG, YANCHAO,
ALIEV, GJUMRAKCH (2020) neoplastic transformation.
Therapy of PAs with aggressive behavior is a complex task. When surgery
The question of what came first—in this case the diagnosis of prostate cancer or its
therapy therapy with miRNA to improve the prognosis of patients with this pathology. © 2022 The Authors
Zhiyong, Ji,
Yeping, Ling,
Pingbo, Chen,
Meng, Yuxiao,
Xu, Shancai,
Wu, Pei,
Wang, Chunlei,
Ilyasova, Tatiana,
Sun, Bowen,
Shi, Huaizhang (2023) of recurrent
serious ischemic events despite standard medical
therapy, has been clinically
challenging. A
ATAS, A.E.,
SARAC, A.,
DIRICAN, A.,
TOPBASI, N.,
UZAR, T.,
RASTGAR, L.,
PANKINA, E.,
OZKAYA, S. (2019) . Although thrombolytic
therapy is controversial, it can be a life-saving procedure
and can be safely used